NANOVIRICIDES INC (NNVC)
US6300873022 - Common Stock
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning!
NNVC Stock Earnings: Nanoviricides Beats EPS for Q3 2024
NNVC stock results show that Nanoviricides beat analyst estimates for earnings per share the third quarter of 2024.
3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire
Discover three nanotech stocks poised for explosive growth in a booming market. Explore their potential for massive returns.
NanoViricides reports positive safety results for COVID drug candidate (NYSE:NNVC)
NanoViricides (NNVC) has reported positive Phase 1 safety data for its antiviral drug NV-CoV-2 for the treatment of COVID and RSV. Read more here.
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
By David Willey, Benzinga
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
By David Willey, Benzinga
The 7 Most Promising Penny Stocks to Buy in June
These top penny stocks for June look to have legitimate catalysts that can certainly send share prices higher.
NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City
SHELTON, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- (via IBN) -- NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), a clinical stage global leader...
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
By David Willey, Benzinga
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
By Ernest Dela Aglanu, Benzinga
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It
By Ernest Dela Aglanu, Benzinga